HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Metastatic castration-resistant prostate cancer: changing landscape with cabazitaxel.

Abstract
Docetaxel is the standard first-line chemotherapy for men with metastatic castration-resistant prostate cancer. Until recently, there was no standard therapy after failure of docetaxel treatment. Cabazitaxel has been shown to improve overall survival in this setting. As a result, the treatment paradigm for mCRPC is changing rapidly. The improved survival shown with cabazitaxel provides an important new opportunity to treat men with mCRPC after docetaxel treatment. Despite the toxicity recorded in the pivotal study, subsequent trials have shown that cabazitaxel is a safe drug. Patient selection and the optimal interval between prior docetaxel treatment and cabazitaxel remain the critical issues. According to a subanalysis of the various studies discussed in this review, there is a patient profile that will probably benefit from use of cabazitaxel after docetaxel failure. Cabazitaxel represents a new treatment option for patients with prostate cancer.
AuthorsOvidio Fernández, Javier Afonso, Sergio Vázquez, Begoña Campos, Matín Lázaro, Luis León, Luis M Antón Aparicio
JournalAnti-cancer drugs (Anticancer Drugs) Vol. 25 Issue 3 Pg. 237-43 (Mar 2014) ISSN: 1473-5741 [Electronic] England
PMID24217332 (Publication Type: Journal Article, Review)
Chemical References
  • Antineoplastic Agents
  • Taxoids
  • Docetaxel
  • cabazitaxel
Topics
  • Antineoplastic Agents (administration & dosage, therapeutic use)
  • Docetaxel
  • Humans
  • Male
  • Neoplasm Metastasis
  • Prostatic Neoplasms, Castration-Resistant (drug therapy, mortality, pathology)
  • Survival Rate
  • Taxoids (administration & dosage, therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: